Histopathologic characteristics of therapy-associated cutaneous neoplasms with vemurafenib, a selective BRAF kinase inhibitor, used in the treatment of melanoma.
Phase of Trial: Phase II
Latest Information Update: 22 Dec 2015
At a glance
- Drugs Vemurafenib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- 22 Dec 2015 New trial record